BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Guilford Pharmaceuticals Inc. (GLFD) Stockholders Vote To Approve MGI Pharma Inc. (MOGN) Merger


10/19/2005 5:13:08 PM

BALTIMORE, Sept. 29 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. today announced that its stockholders approved the merger transaction pursuant to which Guilford will become a wholly-owned subsidiary of MGI PHARMA, INC. , an oncology and acute care focused biopharmaceutical company located in Bloomington, Minnesota. The transaction is expected to be completed on October 3, 2005.

Under the terms of the transaction, each share of Guilford common stock will be exchanged for $1.125 in cash and .1103 of a share of MGI PHARMA common stock. The share exchange ratio is based on an average closing price of $23.80, determined over the five day trading period ending three trading days prior to closing. The average price was within the collar set forth in the Merger Agreement.

About Guilford Pharmaceuticals

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and Aggrastat(R) injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, Aquavan(R) injection, and other drugs for treating Parkinson's disease and peripheral nerve injury. For additional prescribing information about Gliadel and Aggrastat please see http://www.guilfordpharm.com.

About MGI PHARMA

MGI PHARMA, INC. is an oncology and acute care focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), and Kadian(R) (sustained release morphine sulfate) capsules in the United States. The company directly markets its products in the U.S. and collaborates with partners to reach international markets. For more information about MGI PHARMA, please visit http://www.mgipharma.com.

Contact: Guilford Pharmaceuticals Inc.

Stacey Jurchison 410.631.5022 jurchisons@guilfordpharm.com

Guilford Pharmaceuticals Inc.

CONTACT: Stacey Jurchison, Guilford Pharmaceuticals Inc., +1-410-631-5022,jurchisons@guilfordpharm.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->